SNDX · Insider Trading
Syndax Pharmaceuticals, Inc.
Every open-market purchase and sale reported by SNDX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-09 | Michael A Metzger | Chief Executive Officer | MIXED | — | −$578.22K |
| 2026-06-12 | Nicholas A.J. Botwood | Head of R&D, CMO | MIXED | −11,765 | −$440.82K |
| 2026-06-02 | Michael A Metzger | Chief Executive Officer | Sell | −6,847 | −$130.02K |
| 2026-06-02 | Keith A. Goldan | Chief Financial Officer | Sell | −1,177 | −$22.35K |
| 2026-02-10 | Keith A. Goldan | Chief Financial Officer | Sell | −3,410 | −$71.71K |
| 2026-02-10 | Michael A Metzger | Chief Executive Officer | Sell | −17,159 | −$360.82K |
| 2026-02-06 | Pierre Legault | Director | A | +24,000 | — |
| 2026-02-06 | Dennis Podlesak | Director | A | +48,000 | — |
| 2026-02-06 | Keith Katkin | Director | A | +24,000 | — |
| 2026-02-06 | Aleksandra Rizo | Director | A | +24,000 | — |
| 2026-02-06 | Jennifer Jarrett | Director | A | +24,000 | — |
| 2026-02-06 | Nicholas A.J. Botwood | Head of R&D, CMO | A | +60,000 | — |
| 2026-02-06 | Martin H. Huber Jr. | Director | A | +24,000 | — |
| 2026-02-06 | Michael A Metzger | Chief Executive Officer | MIXED | +210,188 | −$152.84K |
| 2026-02-06 | Keith A. Goldan | Chief Financial Officer | MIXED | +51,387 | −$32.59K |
| 2025-12-01 | Keith A. Goldan | Chief Financial Officer | G | −1,224 | — |
| 2025-09-08 | Michael A Metzger | Chief Executive Officer | MIXED | — | −$867.38K |
| 2025-08-18 | Dennis Podlesak | Director | MIXED | — | −$460.38K |
| 2025-08-07 | Keith A. Goldan | Chief Financial Officer | J | +1,226 | +$10.34K |
| 2025-07-18 | Michael A Metzger | Chief Executive Officer | Sell | −7,534 | −$69.95K |
| 2025-07-18 | Keith A. Goldan | Chief Financial Officer | Sell | −1,296 | −$12.03K |
| 2025-05-19 | Keith A. Goldan | Chief Financial Officer | Buy | +3,000 | — |
| 2025-05-19 | Martin H. Huber Jr. | Director | Buy | +5,000 | +$44.95K |
| 2025-05-19 | Keith Katkin | Director | Buy | +10,000 | +$91.12K |
| 2025-05-19 | Nicholas A.J. Botwood | Head of R&D, CMO | Buy | +11,765 | +$105.83K |
| 2025-03-17 | Michael A Metzger | Chief Executive Officer | M | +6,074 | +$43.73K |
| 2025-03-06 | Michael A Metzger | Chief Executive Officer | MIXED | — | −$61.30K |
| 2025-02-12 | Keith A. Goldan | Chief Financial Officer | Sell | −3,777 | −$58.56K |
| 2025-02-12 | Neil Gallagher | President, Head of R&D | Sell | −4,618 | −$71.60K |
| 2025-02-12 | Michael A Metzger | Chief Executive Officer | Sell | −13,288 | −$206.02K |
| 2025-02-07 | William Meury | Director | A | +25,000 | — |
| 2025-02-07 | Aleksandra Rizo | Director | A | +25,000 | — |
| 2025-02-07 | Martin H. Huber Jr. | Director | A | +25,000 | — |
| 2025-02-07 | Jennifer Jarrett | Director | A | +25,000 | — |
| 2025-02-07 | Keith Katkin | Director | A | +25,000 | — |
| 2025-02-07 | Keith A. Goldan | Chief Financial Officer | A | +41,900 | — |
| 2025-02-07 | Pierre Legault | Director | A | +25,000 | — |
| 2025-02-07 | Neil Gallagher | President, Head of R&D | A | +41,900 | — |
| 2025-02-07 | Dennis Podlesak | Director | A | +50,000 | — |
| 2025-02-07 | Michael A Metzger | Chief Executive Officer | A | +149,500 | — |
| 2024-06-17 | Keith A. Goldan | Chief Financial Officer | Buy | +1,250 | +$25.04K |
| 2024-05-16 | Aleksandra Rizo | Director | A | +35,000 deriv. | — |
| 2024-02-09 | Pierre Legault | Director | A | +17,000 | — |
| 2024-02-09 | William Meury | Director | A | +17,000 | — |
| 2024-02-09 | Jennifer Jarrett | Director | A | +17,000 | — |
| 2024-02-09 | Briggs Morrison | Director | A | +17,000 | — |
| 2024-02-09 | Dennis Podlesak | Director | A | +34,000 | — |
| 2024-02-09 | Neil Gallagher | President, Head of R&D | A | +47,813 | — |
| 2024-02-09 | Keith Katkin | Director | A | +17,000 | — |
| 2024-02-09 | Michael A Metzger | Chief Executive Officer | A | +146,250 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Michael A Metzger | Chief Executive Officer | 517,218 | $6.84M |
| Dennis Podlesak | Director | 239,763 | $3.17M |
| Keith A. Goldan | Chief Financial Officer | 139,252 | $1.84M |
| Keith Katkin | Director | 124,000 | $1.64M |
| Pierre Legault | Director | 114,000 | $1.51M |
| Jennifer Jarrett | Director | 114,000 | $1.51M |
| Martin H. Huber Jr. | Director | 103,000 | $1.36M |
| Nicholas A.J. Botwood | Head of R&D, CMO | 95,165 | $1.26M |
| William Meury | Director | 90,000 | $1.19M |
| Neil Gallagher | President, Head of R&D | 85,095 | $1.12M |
| Aleksandra Rizo | Director | 49,000 | $647.78K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SNDX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.